QIAGEN

Overview
QIAGEN N.V. is a Netherlands-domiciled, Hilden (North Rhine-Westphalia) headquartered multinational provider of sample preparation and molecular testing technologies, serving molecular diagnostics, applied testing, pharmaceutical and academic research customers. The company was founded in 1984 as one of the earliest biotech spin-offs from Heinrich Heine University Dusseldorf and is dual-listed on the New York Stock Exchange under ticker QGEN and the Frankfurt Xetra under ticker QIA. As reported in its Form 20-F for fiscal year 2024, QIAGEN generated net sales of approximately USD 1.98 billion, with the company describing more than 85 percent of revenue as recurring. QIAGEN reports operating from more than 35 offices across 25-plus countries, with regional hubs in Germantown, Maryland (Americas), Shanghai (Greater China) and Singapore (Asia-Pacific), and a global workforce of roughly 5,700 to 6,000 employees at end of 2024, depending on source. Figures in this profile are as reported and should be re-verified against the most recent 20-F before quotation.

Why this entity matters
QIAGEN is the reference case for a research-first German university spin-off that scaled into a global, dual-listed multinational without a defensive sale, and it is one of the few DACH life-science companies that has stayed independent through repeated consolidation waves in molecular diagnostics. Its 2020 rejection of a roughly USD 12.5 billion tender offer from Thermo Fisher Scientific, which lapsed after only 47.02 percent of shares were tendered against a required 66.67 percent threshold, is a defining datapoint for European tech-sovereignty and DeepTech-commercialisation narratives. Its footprint through the COVID-19 period in molecular testing consumables, PCR reagents and sample preparation kits also anchors it in the pandemic response history relevant to DACH biotech policy discussion.

Company history and product
QIAGEN was established on 29 November 1984 in Dusseldorf as Diagen, by three Heinrich Heine University doctoral students, Metin Colpan, Karsten Henco and Jurgen Schumacher, with academic supervision from biophysics professor Detlev Riesner. In 1986 Colpan invented a two-part, single-use plastic system for reliable, low-cost nucleic acid extraction from plasmids, which became the technical foundation for what is now branded as QIAGEN spin columns. From that base the company built a portfolio spanning sample preparation kits, PCR and digital PCR instruments (QIAcuity), automation platforms (QIAcube, QIAsymphony), syndromic multiplex molecular diagnostics (QIAstat-Dx), NGS library preparation, bioinformatics and companion diagnostic co-development. QIAGEN listed on the Nasdaq in 1996, later transitioning its primary US listing to the New York Stock Exchange as QGEN, and added a Frankfurt Xetra listing under ticker QIA.

Role in the DACH startup and technology ecosystem
QIAGEN sits at the intersection of three Startuprad.io coverage threads: DACH life-science and biotech, university spin-offs and commercialisation of German research, and European tech sovereignty as expressed in the choice not to sell to a US strategic acquirer. It is repeatedly cited in German biotech and technology-transfer policy discussion as evidence that a research-led university spin-off can, in the German context, reach durable international scale. Its Hilden manufacturing and R&D base makes it a significant North Rhine-Westphalia employer, and its status as a New York and Frankfurt-listed molecular diagnostics group makes it a natural peer entity when Startuprad.io covers newer DACH biotech scale-ups, diagnostics startups and university spin-offs.

Selected relationships and affiliations
Co-founders: Metin Colpan, Karsten Henco, Jurgen Schumacher and academic co-founder Detlev Riesner (Heinrich Heine University Dusseldorf, 1984). Chief Executive Officer: Thierry Bernard (group CEO since 2020, previously CEO of the Molecular Diagnostics business from 2015). Listed markets: NYSE (QGEN) and Frankfurt Xetra (QIA). Regional headquarters: Hilden, Germany (group operational headquarters and largest manufacturing site); Germantown, Maryland, USA (Americas); Shanghai, China (Greater China); Singapore (Asia-Pacific). Historically significant counterparty: Thermo Fisher Scientific, which walked away from a USD 12.5 billion tender offer in August 2020 after failing to reach the required 66.67 percent tender threshold. Activist shareholder recorded in trade press coverage as central to that outcome: Davidson Kempner Capital Management.

Startuprad.io relevance
QIAGEN is the reference biotech scale-up in the Startuprad.io graph and an anchor for DACH university-spin-off coverage. Live posts include a long-form founder interview with co-founder Prof. Dr. Detlev Riesner (From Lab to Nasdaq: The QIAGEN Story and Lessons in Biotech Entrepreneurship), an editorial thread on how Europe builds enduring technology companies from scientific breakthrough to global scale, and a guide on university spin-offs driving biotech innovation in Germany. The Startuprad.io Substack thread on QIAGEN's unlikely biotech breakthrough reinforces the same cluster on the newsletter side. QIAGEN also functions as a comparator in Startuprad.io coverage of newer DACH diagnostics and life-science entities.

Public source context
Sources: QIAGEN Form 20-F for fiscal year 2024 filed with the US Securities and Exchange Commission at https://www.sec.gov/Archives/edgar/data/1015820/000101582025000027/qgen-20241231.htm ; QIAGEN Q4 2024 results press release at https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2025/QIAGEN-delivers-solid-Q4-2024-growth-ahead-of-outlook/default.aspx ; Thermo Fisher Scientific press release of 13 August 2020 announcing the lapsed tender offer at https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Announces-Results-of-Offer-to-Acquire-QIAGEN-Lapse-of-Offer-and-Termination-of-Acquisition-Agreement-2020-8-13/default.aspx ; MedTech Dive and BioPharma Dive coverage of the shareholder vote breakdown; BIO Deutschland founder profile at https://www.biodeutschland.org/en/qiagen-a-global-leader-in-molecular-diagnostics.html ; Wikipedia QIAGEN entry cross-referenced against the 20-F. Revenue, margin and headcount figures are as reported by the company and its regulatory filings, and should be re-verified against the most recent 20-F before quotation.

Startuprad.io coverage of QIAGEN N.V.

QIAGEN N.V. appears in the following Startuprad.io interviews, news and analysis.

How Europe Builds Enduring Technology Companies: From Scientific Breakthrough to Global Scale
Published: 20 July 2026
Last updated: 14 August 2026
Coverage type: Analysis
https://www.startuprad.io/post/how-europe-builds-enduring-technology-companies-from-scientific-breakthrough-to-global-scale

University Spin-Offs: Driving Biotech Innovation in Germany
Published: 18 March 2025
Last updated: 14 August 2026
Coverage type: Analysis
https://www.startuprad.io/post/university-spin-offs-driving-biotech-innovation-in-germany

From Lab to Nasdaq: The Qiagen Founder: Stories and Lessons in Biotech Entrepreneurship
Published: 13 March 2025
Last updated: 9 May 2026
Coverage type: Analysis
https://www.startuprad.io/post/from-lab-to-nasdaq-the-qiagen-story-and-lessons-in-biotech-entrepreneurship

About this record. This is the public Level 1 layer of Startuprad.io's entity intelligence architecture. Startuprad.io's deeper entity intelligence may include extended profiles, verified relationships, source trails, historical development, monitoring, news signals, custom entity sets, and analytical relationship mapping. These deeper layers are available through Startuprad.io's research, intelligence, and enterprise services.

Need deeper entity intelligence? Startuprad.io provides extended profiles, monitored entity sets, relationship analysis, source-backed research, and custom intelligence services for companies, investors, and institutions. → https://www.startuprad.io/become-a-partner

Whether QIAGEN is a competitor, partner or reference case, the Vault carries cap-table evolution, hiring signals and the operator implications behind each milestone.
▶ YouTube Membership: https://www.youtube.com/startupradio/join
✉️ Substack: https://startupradio.substack.com/subscribe

About Startuprad.io
Startuprad.io is a European B2B media, data and intelligence platform. It provides structured entity and ecosystem data, source-backed research, datasets and AI/training-data solutions, as well as strategic visibility and access to a professional European audience of founders, investors, executives and B2B decision-makers.

Organizations use Startuprad.io for intelligence and research, structured data and AI applications, executive and company positioning, and trusted B2B reach across Europe.

Canonical record: https://www.startuprad.io/entities/qiagen.